Troglitazone and emerging glitazones: new avenues for potential therapeutic benefits beyond glycemic control
H Horikoshi1, T Hashimoto, T Fujiwara
1Sankyo Pharma Research Institute, La Jolla, CA 92037, USA.
Abstract:
Insulin resistance is characterized as one of the major pathogeneses of type 2 diabetes and has been associated with these same cardiovascular risk factors. Troglitazone, rosiglitazone, and pioglitazone are a new class of oral antidiabetic agents which can ameliorate peripheral insulin resistance in type 2 diabetes. There is considerable evidence that trogliterazone may have beneficial effects on cardiovascular and metabolic abnormalities associated with insulin resistance. There is supportive evidence for positive effects of the other glitazones, but they have been less well studied. These potential benefits span effects ranging from molecular events in the arterial wall to amelioration and/or improvement in lipid parameters known to be associated with atherosclerosis.
More Related Videos
10:08The Evoked Potential Operant Conditioning System EPOCS: A Research Tool and an Emerging Therapy for Chronic Neuromuscular Disorders
Published on: August 25, 2022
06:59A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Published on: November 9, 2016
Related Concept Videos
Introduction Cardiac Emergencies
Benefits of Self-Esteem
Controlled-Potential Coulometry: Electrolytic Methods
The chosen potential...
Emerging Adulthood
Oral Hypoglycemic Agents: Biguanides and Glitazones
Therapeutic Index
